Lilly's $10 Billion Raise Comes With a $2 Billion Asterisk
Q3 was another blowout, but the cleaner story is what happens when one-time items roll off and Foundayo meets diabetes.
LLY · Earnings Call · 2026-10-29
A blowout with a cleaner, smaller core
Eli Lilly's Q3 2026 was another quarter of superlatives. Revenue rose 39% year over year, roughly $7 billion of incremental sales, and management raised full-year financial guidance to $91–$92 billion — about $10 billion above where the year started. The stock has noticed: LLY is up 23% over the last 90 trading days, a fresh breakout for a $1.29 trillion market-cap company.
But the headline has an asterisk, and management put it there itself. “Revenue grew 39% compared to Q3 25.” — Lucas E. Montarce, Chief Financial Officer · 2026-10-29 That is real. So is the caveat:
2026 revenue benefited from approximately $2 billion of 1-time items primarily related to milestones payments and changes in estimates for rebates and discounts that we do not expect to recur.
In Q3 alone, about $900 million came from milestones and rebate-estimate changes. Strip that out and the underlying growth is still exceptional — but less than the reported number, and 2027 consensus now has to absorb the roll-off.
The last filed quarter shows the operating machine underneath: Q2 2026 revenue of $23.0 billion, up 48% year over year, with an operating margin of 40.2% and free cash flow of $10.5 billion. Yet the valuation has compressed even as the stock has run: 14.2 times revenue, 36% below the peak. The market is paying less per dollar of sales because earnings are growing faster. That is a good problem — but it also means the next leg depends on durability, not another headline beat.
The Bridge is the demand engine now
The most important commercial development is the GLP-1 bridge program. Since the July 1 launch, more than half a million people have filled a Lilly prescription through the Medicare pilot. Seven of ten new bridge patients start on a Lilly obesity medicine, roughly 75% choose injectables, and — critically — “about 80% of the people getting treatment under bridge are naive or have not been on therapy in the past.” — Ilya Yuffa, Executive Vice President, President of Lilly Diabetes and Obesity · 2026-10-29 That is a purer expansion signal than the 60–70% new-patient mix management cited on the Q2 call. The program is also a policy option: David Ricks argued the early uptake and a USC estimate of more than $20 billion of cumulative Medicare savings over ten years support making the coverage shift permanent. The risk is obvious — it is still a pilot, and the 2028 Part D handoff is not done.
This is where the cash pay story is migrating. LillyDirect and self-pay were the consumer narrative in prior quarters; now the Bridge is the scaled access channel, with cash pay still relevant but less of the spotlight. The pricing logic has been consistent: on the Q1 call, Ricks said “pretty much every time we reduce pricing, we see a pretty large expansion.” — David Ricks, Chair and CEO · 2026-04-30 On the Q2 call, Ilya Yuffa put the injectable share at “about 80% of people that are getting treatment are injectable” — Ilya Yuffa, Executive Vice President, President of Lilly Diabetes and Obesity · 2026-08-05; Q3's 75% is a modest mix shift toward orals, not a collapse. Both channels expand the incretin business; neither is immune to net-price pressure.
Foundayo's second leg
Foundayo was the question mark in prior calls. On the Q2 call, Yuffa was still describing an inflection from a small base: “we're almost doubling the volume that we had just a month ago.” — Ilya Yuffa, Executive Vice President, President of Lilly Diabetes and Obesity · 2026-08-05 Three months later the base is real: more than 500,000 TRx in Q3, new-patient volume doubled sequentially, roughly four in ten patients starting an oral obesity medicine choose Foundayo, and about 25% of patients are already on a maintenance dose — a higher share than the Wegovy oral launch, management says. The next catalyst is Foundayo in type 2 diabetes; the U.S. regulatory action is expected in Q4, and Ricks notes that roughly half of U.S. GLP-1 volume is still diabetes. That is a second market, not just a line extension.
Outside the U.S., Foundayo is in four markets and under review in more than 40, with a major rollout expected in 2027. The launch economics are still early, but the strategic point is that Lilly now has an oral on-ramp, an injectable cornerstone, and a pipeline of next-generation incretins — a portfolio approach rather than a single-product bet. Kenneth Custer framed the size of the prize simply: “1 hundred and 10 million or so people living in The US with obesity or overweight. Internationally. That number has a B at the start of it.” — Kenneth Custer, Senior Vice President, Head of Diabetes and Obesity · 2026-10-29
The pipeline is no longer just tirzepatide
The Q3 pipeline news explains why the keyword set has shifted. Olora-TZP, the amylin-plus-tirzepatide combination, delivered 23.3% weight loss at 48 weeks in Phase 2 — 57% more than tirzepatide — with A1C down 2.9 points and more than three-quarters of patients below 5.7%. The caveat is tolerability: the highest-dose arm had more discontinuations, and Phase 3 will use slower titration. Retatrutide's TRANSCEND T2D 2 head-to-head showed “more than doubled the weight loss of 2 milligrams semaglutide.” — Daniel Skovronsky, Chief Scientific and Medical Officer · 2026-10-29 In neuroscience, Trailblazer 3 remains the binary event for early symptomatic Alzheimer's, while atopic dermatitis and a weekly basal insulin broaden the non-obesity base. R&D is running at roughly 17% of revenue, and the company is simultaneously building two U.S. plants — $6.5 billion in Houston and $5 billion in Richmond — which helps explain an effective net cash position of -$38.9 billion. Growth is being funded, not just harvested.
What actually changed
The subtlest change is in how management talks about guidance. Steve Scala asked why Lilly's guidance has repeatedly undershot. Ricks' answer was unusually candid: “we are in the middle of the largest new category expansion in the history of the pharmaceutical industry.” — David A. Ricks, Chair and Chief Executive Officer · 2026-10-29 He added that Lilly prefers “to give a posture investors can rely on versus one that is more speculative” — David A. Ricks, Chair and Chief Executive Officer · 2026-10-29, and that “as time goes on, I suspect we will have fewer and fewer of those never before done things. And the guidance can become more predictable.” — David A. Ricks, Chair and Chief Executive Officer · 2026-10-29 If that is true, the stock's next re-rating could come from a lower risk premium on guidance rather than another $10 billion raise.
But the $2 billion one-time item is the first test of that new predictability. The 2027 setup is genuinely strong — full-year Bridge, Foundayo in type 2 diabetes, Mounjaro international penetration, and a deep pipeline — yet net realized price remains a headwind, and the one-time boost does not repeat. The bull case is that Lilly is transitioning from a never-been-done story to a durable compounder; the bear case is that the market is capitalizing a beat that was partly timing. At 14 times sales and 42 times net income, the stock is not cheap enough to ignore that distinction. The quarter was a genuine name-in-motion; the next one has to prove the motion is clean.